Engineered antibody fragments and the rise of single domains

[1]  John W. Park,et al.  Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis , 2008, Biotechnology progress.

[2]  H. Rammensee,et al.  Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells in vitro and in vivo , 2005, International journal of cancer.

[3]  P. D. de Groot,et al.  A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. , 2005, Blood.

[4]  H. Kosmehl,et al.  Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy , 2005 .

[5]  Andreas Plückthun,et al.  Engineered proteins as specific binding reagents. , 2005, Current opinion in biotechnology.

[6]  L. Wyns,et al.  Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. , 2005, Journal of molecular biology.

[7]  S. Gambhir,et al.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.

[8]  Ziding Feng,et al.  Optimized Normalization for Antibody Microarrays and Application to Serum-Protein Profiling*S , 2005, Molecular & Cellular Proteomics.

[9]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[10]  P. Hoffmann,et al.  Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.

[11]  Mengji Lu,et al.  Immunization with the Gene Expressing Woodchuck Hepatitis Virus Nucleocapsid Protein Fused to Cytotoxic-T-Lymphocyte-Associated Antigen 4 Leads to Enhanced Specific Immune Responses in Mice and Woodchucks , 2005, Journal of Virology.

[12]  G. Vriend,et al.  Induced refolding of a temperature denatured llama heavy‐chain antibody fragment by its antigen , 2005, Proteins.

[13]  Laurent Chiche,et al.  New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. , 2005, Biochemistry.

[14]  Michael Wunderlich,et al.  Stabilization of the cold shock protein CspB from Bacillus subtilis by evolutionary optimization of Coulombic interactions. , 2005, Journal of molecular biology.

[15]  K. Christopher Garcia,et al.  Structure of a γδ T Cell Receptor in Complex with the Nonclassical MHC T22 , 2005, Science.

[16]  L. Wyns,et al.  Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires* , 2005, Journal of Biological Chemistry.

[17]  S. Shen,et al.  Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. Kimmig,et al.  Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. , 2005, Cancer research.

[19]  R. Ober,et al.  From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. , 2005, Molecular biology of the cell.

[20]  A. Arnold,et al.  T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. , 2005, Vaccine.

[21]  Michael P. Levens,et al.  Engineering high affinity superantigens by phage display. , 2005, Journal of molecular biology.

[22]  W. Wels,et al.  A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. , 2005, Journal of molecular biology.

[23]  Targeting malignant B‐cell lymphoma with a humanized anti‐CD22 scFv‐angiogenin immunoenzyme ‡ , 2005, British journal of haematology.

[24]  M. Flajnik,et al.  Shark immunity bites back: affinity maturation and memory response in the nurse shark, Ginglymostoma cirratum , 2005, European journal of immunology.

[25]  D. Vallera,et al.  Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. , 2005, Leukemia research.

[26]  P. Linsley.  New look at an old costimulator , 2005, Nature Immunology.

[27]  Dan Lu,et al.  A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 , 2005, Molecular Cancer Therapeutics.

[28]  Jing Wu,et al.  Augmentation of antitumor effects of p53 Gene therapy by combination with HDAC inhibitor , 2005, Cancer biology & therapy.

[29]  V. Streltsov,et al.  Do sharks have a new antibody lineage? , 2005, Immunology letters.

[30]  Mohan Doss,et al.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.

[31]  I. Pastan,et al.  HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity , 2005, Clinical Cancer Research.

[32]  D. Stuart,et al.  Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.

[33]  Ross S Chambers,et al.  High-throughput antibody production. , 2005, Current opinion in chemical biology.

[34]  S. Batra,et al.  The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. , 2005, Nuclear medicine and biology.

[35]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[36]  C. James,et al.  Rescue and propagation of fully retargeted oncolytic measles viruses , 2005, Nature Biotechnology.

[37]  D. Lauffenburger,et al.  Integrating cell-level kinetic modeling into the design of engineered protein therapeutics , 2005, Nature Biotechnology.

[38]  S. Gambhir,et al.  Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.

[39]  Sanjiv S Gambhir,et al.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.

[40]  R. Begent,et al.  Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  G. Vriend,et al.  Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo , 2005, Applied and Environmental Microbiology.

[42]  B. Shen,et al.  A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. , 2005, Journal of immunological methods.

[43]  E. Adams,et al.  Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. , 2005, Science.

[44]  H. Kosmehl,et al.  Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. , 2005, International journal of cancer.

[45]  D. Goldenberg,et al.  Perspectives on cancer therapy with radiolabeled monoclonal antibodies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  David W. Colby,et al.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Rybak,et al.  Antigen binding and stability properties of non‐covalently linked anti‐CD22 single‐chain Fv dimers , 2004, FEBS letters.

[48]  L. Wyns,et al.  Chemical Basis for the Affinity Maturation of a Camel Single Domain Antibody* , 2004, Journal of Biological Chemistry.

[49]  Serge Muyldermans,et al.  Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen* , 2004, Journal of Biological Chemistry.

[50]  T. Lüscher,et al.  Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin , 2004, Circulation research.

[51]  K. Chester,et al.  Engineered single chain antibody fragments for radioimmunotherapy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[52]  A L Ghindilis,et al.  Immunoassays based on electrochemical detection using microelectrode arrays. , 2004, Biosensors & bioelectronics.

[53]  R. Jordan,et al.  Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation , 2004, Platelets.

[54]  Uwe Karsten,et al.  Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. , 2004, Journal of molecular biology.

[55]  B Tidor,et al.  Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. , 2004, Journal of molecular biology.

[56]  H. Goldschmidt,et al.  Combined effect of recombinant CD19×CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma , 2004, Anti-cancer drugs.

[57]  G. Winter,et al.  Selection of optical biosensors from chemisynthetic antibody libraries. , 2004, Protein engineering, design & selection : PEDS.

[58]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[59]  K Dane Wittrup,et al.  Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. , 2004, Journal of molecular biology.

[60]  I. Wilson,et al.  Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme , 2004, Science.

[61]  P. Parren,et al.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.

[62]  M. Brechbiel,et al.  A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice , 2004, Cancer Research.

[63]  Dennis R. Burton,et al.  Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody , 2022 .

[64]  J. Varghese,et al.  Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Carolyn R. Bertozzi,et al.  Chemical remodelling of cell surfaces in living animals , 2004, Nature.

[66]  G. Winter,et al.  Aggregation-resistant domain antibodies selected on phage by heat denaturation , 2004, Nature Biotechnology.

[67]  L. Dinkelborg,et al.  Molecular targeting of angiogenesis for imaging and therapy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  T. Allen,et al.  Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.

[69]  Paul J Yazaki,et al.  Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer , 2004, Clinical Cancer Research.

[70]  T. Rabbitts,et al.  Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. , 2004, Current molecular medicine.

[71]  D. Burton,et al.  Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[72]  C. Demangel,et al.  Targeting Dendritic Cells with Antigen-Containing Liposomes , 2004, Cancer Research.

[73]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[74]  R. Kontermann,et al.  Recombinant bispecific antibodies for the targeting of adenoviruses to CEA‐expressing tumour cells: a comparative analysis of bacterially expressed single‐chain diabody and tandem scFv , 2004, The journal of gene medicine.

[75]  S. Sharma,et al.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT) , 2004, British Journal of Cancer.

[76]  S. Muyldermans,et al.  An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. , 2004, Bioconjugate chemistry.

[77]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[78]  L. James,et al.  Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.

[79]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[80]  M. Foley,et al.  Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1 , 2004, Proteins.

[81]  M. Little,et al.  Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. , 2004, Protein engineering, design & selection : PEDS.

[82]  F. Legall,et al.  Recent advances in the generation of bispecific antibodies for tumor immunotherapy. , 2004 .

[83]  S. Russell,et al.  Antibody-targeted cell fusion , 2004, Nature Biotechnology.

[84]  L. Álvarez-Vallina,et al.  Antibodies and gene therapy: teaching old 'magic bullets' new tricks. , 2004, Trends in immunology.

[85]  Dennis R. Burton,et al.  Human antibody–Fc receptor interactions illuminated by crystal structures , 2004, Nature Reviews Immunology.

[86]  T. Dottorini,et al.  Crystal structure of a human VH: requirements for maintaining a monomeric fragment. , 2004, Biochemistry.

[87]  L. Wyns,et al.  Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies , 2004, Journal of Biological Chemistry.

[88]  T. L. Brown,et al.  MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis , 2003, Apoptosis.

[89]  K. Medzihradszky,et al.  Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. , 2003, Glycobiology.

[90]  S. Kipriyanov,et al.  Recent advances in the generation of bispecific antibodies for tumor immunotherapy. , 2004, Current opinion in drug discovery & development.

[91]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.

[92]  W. Mcbride,et al.  Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  P. Rosenthal,et al.  Structure of an influenza neuraminidase-diabody complex by electron cryomicroscopy and image analysis. , 2003, Journal of molecular biology.

[94]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[95]  Junho Chung,et al.  Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors* , 2003, Journal of Biological Chemistry.

[96]  W. Gibson.  Faculty Opinions recommendation of Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. , 2003 .

[97]  R. Klemenz,et al.  Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy , 2003, Gene Therapy.

[98]  P. Hudson,et al.  Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. , 2003, European journal of biochemistry.

[99]  T. Rabbitts,et al.  Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. , 2003, Journal of molecular biology.

[100]  R. Vile,et al.  Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells1 , 2003, The Journal of Immunology.

[101]  Carl W. Miller,et al.  Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. , 2003, Cancer letters.

[102]  J. Rizo,et al.  Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice , 2003, Nature Biotechnology.

[103]  T. Rabbitts,et al.  De novo production of diverse intracellular antibody libraries. , 2003, Nucleic acids research.

[104]  Dan S. Tawfik,et al.  Antibody Multispecificity Mediated by Conformational Diversity , 2003, Science.

[105]  A. Wu,et al.  The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. , 2003, Journal of molecular biology.

[106]  Olan Dolezal,et al.  Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium. , 2003, Protein engineering.

[107]  A. Kortt,et al.  Generation of recombinant multimeric antibody fragments for tumor diagnosis and therapy. , 2003, Methods in molecular biology.

[108]  P. Hudson,et al.  Engineered antibodies , 2003, Nature Medicine.

[109]  Dan S. Tawfik,et al.  Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry , 2002, FEBS Letters.

[110]  A. Nesbitt,et al.  Formatting antibody fragments to mediate specific therapeutic functions. , 2002, Biochemical Society transactions.

[111]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[112]  Jennifer L Ong,et al.  Isolation of receptor–ligand pairs by capture of long-lived multivalent interaction complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[113]  L. Hope-Stone,et al.  Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study , 2002, British Journal of Cancer.

[114]  C. Halin,et al.  Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.

[115]  M. Dohlsten,et al.  Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen , 2001, British Journal of Cancer.

[116]  P. Carter,et al.  Bispecific human IgG by design. , 2001, Journal of immunological methods.

[117]  U. Nielsen,et al.  Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. , 2000, Cancer research.

[118]  V. Diehl,et al.  Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. , 1999, Cancer research.

[119]  T. Orntoft,et al.  Clinical aspects of altered glycosylation of glycoproteins in cancer , 1999, Electrophoresis.

[120]  A. Murzin,et al.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[121]  G. Winter,et al.  Retargeting serum immunoglobulin with bispecific diabodies , 1997, Nature Biotechnology.

[122]  P. Iliades,et al.  Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.

[123]  L. Presta,et al.  Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.

[124]  P. McCarthy,et al.  A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. , 1996, Transplantation.

[125]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[126]  K. Fujimori,et al.  Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. , 1991, Cancer research.

[127]  P. T. Jones,et al.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.

[128]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[129]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[130]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[131]  R. R. Robinson,et al.  Escherichia coli secretion of an active chimeric antibody fragment. , 1988, Science.